FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Hicks Laurence
   2. Issuer Name and Ticker or Trading Symbol
Arch Therapeutics, Inc. [ARTH] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET SUITE 6		 3. Date of Earliest Transaction (Month/Day/Year)
07/06/2022
(Street)

FRAMINGHAM, MA 01702		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/06/2022   A(1)   108,652 A (1) 108,652 I By Drake Partners Equity LLC (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Senior Secured Convertible Notes (1) (3) (3) 07/06/2022   A   36,000     (3)   (3) Common Stock 787,746 (3) (1) $ 36,000 D  
Warrants (1) (4) $ 0.0497 07/06/2022   A   724,346   07/06/2022(4) 07/06/2027 Common Stock 724,346 (1) 724,346 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Hicks Laurence
C/O ARCH THERAPEUTICS, INC.
235 WALNUT STREET SUITE 6
FRAMINGHAM, MA 01702		   X      

Signatures

 /s/ Laurence Hicks   07/08/2022
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares of common stock, senior secured convertible notes (the "Notes") and warrants were issued to the Reporting Person in connection with a convertible note offering entered into by the Reporting Person and the Issuer (the "Offering"), which Offering was approved by the Issuer's Board of Directors and, in accordance with Rule 16b-3(d)(1) of the Exchange Act (the "Act"), is exempt from Section 16(b) of the Act pursuant to Rule 16b-3(e) promulgated thereunder.
(2) As a managing member of Drake Partners Equity, LLC, the Reporting Person may be determined to have beneficial ownership of the shares reported herein.
(3) The Notes become due and payable on January 6, 2024, bear interest at a rate of 10% per annum, are convertible at the option of the holder pursuant to certain provisions with an initial conversion price of $0.0457, contain customary events of default and are subject to certain beneficial ownership limitations.
(4) Conversion of the warrants is subject to certain beneficial ownership limitations.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.